Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Barriers and Facilitators of Persistence With Adjuvant Osimertinib
This is a cross-sectional, non-treatment qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage NSCLC in China. Approximately 100 you would be enrolled, comprising around 85 patients and 15 physicians.
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 100 people at Beijing. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Cross-sectional Qualitative Study to Identify Barriers and Facilitators of Persistence With 3rd Generation EGFR-TKI Osimertinib as Adjuvant Treatment (SECURE)
Primary outcome (registry wording): Barriers to persistence
Who it is for (from inclusion criteria)
Ages 18 Years to any
For off treatment patients, discontinuation or completion of osimertinib is required to occur within 6 months by screening
Who the registry excludes
Prior receipt of 3rd generation EGFR-TKI as adjuvant therapy as part of any treatment clinical trial
Prior receipt of 1st generation EGFR-TKIs as adjuvant therapy
Evidence of cognitive impairment that would likely to interfere with participation in an interview, as informally assessed during screening
Unaware of or do not understand their own medical condition
who can join:
Licensed medical oncologists, thoracic surgeons, or pulmonologists with experience of prescribing osimertinib as adjuvant treatment and actively managing patients who will participate the interview
Managed 5 patients with early-stage NSCLC receiving osimertinib within the past 6 months
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate.
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07542210?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07542210?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.